{"id":"W4417004940","doi":"10.1182/blood-2025-1020","title":"Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Jewish General Hospital","funders":"","keywords":"Rituximab; Follicular lymphoma; Refractory (planetary science); Clinical endpoint; Phases of clinical research; Cytokine release syndrome; Lymphoma; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001428962,0.0004063925,0.00118101,0.0002835387,0.0002603773,0.0007829418,0.0003696874,0.0005043347,0.001719913],"category_scores_gemma":[0.001098055,0.0002395028,0.001640194,0.0003394566,0.0002986942,0.0006792445,0.0003361818,0.001571854,0.0002760779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006294379,"about_ca_system_score_gemma":0.0004897518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005762222,"about_ca_topic_score_gemma":0.001199739,"domain_scores_codex":[0.9994596,0.0001870078,0.00004503301,0.0001442622,0.00005443147,0.0001096616],"domain_scores_gemma":[0.9990157,0.0002518735,0.000294618,0.00009868522,0.0000490612,0.0002899923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7957906,0.004352844,0.09699821,0.0004718048,0.004973792,0.0002669081,0.0001525765,0.002075225,0.00971385,0.0001151635,0.001462951,0.08362608],"study_design_scores_gemma":[0.1178897,0.3396616,0.5146058,0.0001944692,0.01169616,0.0008391995,0.0001665717,0.005224688,0.004740277,0.0004724057,0.004434446,0.00007481001],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968385,0.001919064,0.0001899619,0.00006865009,0.00003313495,0.00007158768,0.0004356388,0.0000154956,0.0004278983],"genre_scores_gemma":[0.9986811,0.0002528597,0.00008953329,0.00009584402,0.00003811267,0.00006291121,0.0005371798,0.000002311499,0.0002401423],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001719913,"threshold_uncertainty_score":0.007557154,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004965107923882109,"score_gpt":0.2252899563917081,"score_spread":0.220324848467826,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}